Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Exenatide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R known ✓ | P43220 | 15/20 | 0.75 |
| ▸ | GCGR | P47871 | 9/20 | 0.75 |
| ▸ | GIPR | P48546 | 6/20 | 0.74 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.73 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.73 |
| ▸ | CCKBR | P32239 | 4/20 | 0.70 |
| ▸ | CALCR | P30988 | 3/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Exenatide SCHEMBL14634818 | 0.95 | GLP1R (0.81) | GLP1RGCGRGIPRCCKBR | |
| Exenatide SCHEMBL29710890 | 0.95 | GLP1R (0.81) | GLP1RGCGRGIPRCCKBR | |
| Exenatide SCHEMBL20509814 | 0.95 | GLP1R (0.81) | GLP1RGCGRGIPRCCKBR | |
| SCHEMBL29429437 | 0.95 | GLP1R (0.81) | GLP1RGCGRGIPRCCKBR | |
| Exenatide SCHEMBL29827241 | 0.95 | GLP1R (0.81) | GLP1RGCGRGIPRCCKBR | |
| SCHEMBL31072728 | 0.95 | GLP1R (0.81) | GLP1RGCGRGIPRCCKBR | |
| Exenatide SCHEMBL30947451 | 0.95 | GLP1R (0.79) | GLP1RGCGRGIPR | |
| Exenatide SCHEMBL28323280 | 0.95 | GLP1R (0.81) | GLP1RGCGRGIPRCCKBR | |
| Exenatide SCHEMBL28285812 | 0.95 | GLP1R (0.82) | GLP1RGCGRGIPRCCKBR | |
| Exenatide SCHEMBL29503493 | 0.94 | GLP1R (0.80) | GLP1RGCGRGIPRCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11234 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260148822-A1 | MACHINE LEARNING ARCHITECTURES TO DETERMINE USER RESPONSIVENESS BASED ON MULTI-MODAL MEASUREMENT DATA | Click Therapeutics, Inc. (US) | 2026-05-28 | — | — | US | claimed |
| US-20260137648-A1 | COMPOSITIONS COMPRISING SELECTIVE ANDROGEN RECEPTOR MODULATOR COMPOUNDS IN COMBINATION WITH WEIGHT LOSS DRUGS AND USES THEREOF FOR INCREMENTAL WEIGHT LOSS AND MANAGEMENT OF ADVERSE SIDE EFFECTS OF WEIGHT LOSS DRUGS ON BODY COMPOSITION | VERU INC. (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026099869-A1 | DIGITAL THERAPEUTICS AND COMBINATION THERAPY FOR THE TREATMENT OF PARKINSON'S DISEASE | REMEPY HEALTH LTD (IL) | 2026-05-15 | — | — | WO | claimed |
| WO-2026099117-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1 ANALOG AND AN INORGANIC MESOPOROUS MATERIAL | MERCK PATENT GMBH (DE) | 2026-05-15 | — | — | WO | claimed |
| US-20260132130-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | BIOAGE LABS INC (US) | 2026-05-14 | — | — | US | claimed |
| US-20260130880-A1 | DIGITAL THERAPEUTICS AND COMBINATION THERAPY FOR THE TREATMENT OF PARKINSONS DISEASE | REMEPY HEALTH LTD (IL) | 2026-05-14 | — | — | US | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| EP-4739301-A1 | COMPOSITIONS CONTAINING, AND COMBINATION THERAPIES USING BEMPEDOIC ACID AND A GLP-1 RECEPTOR AGONIST | Esperion Therapeutics, Inc. (US) | 2026-05-13 | — | — | EP | claimed |
| US-12622947-B2 | Pharmaceutical composition for treating levodopa-induced dyskinesia or for suppressing progression thereof | PEPTRON, INC. (KR) | 2026-05-12 | — | — | US | claimed |
| CN-122005762-A | Tenipotene oral self-emulsifying preparation and preparation method thereof | 深圳翰宇药业股份有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-114127105-A | Anti-metallothionein antibodies and uses thereof | 康涅狄格大学 | 2022-03-01 | — | — | CN | claimed |
| CN-114081867-A | Method for improving drug loading capacity of microspheres | 中国药科大学 | 2022-02-25 | — | — | CN | claimed |
| EP-3658115-B1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AT LEAST HUMAN INSULIN A21G AND A PRANDIAL ACTION GLUCAGON SUPPRESSOR | ADOCIA (FR) | 2022-02-23 | — | — | EP | claimed |
| EP-3955913-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES | ENZYCHEM LIFESCIENCES (KR) | 2022-02-23 | — | — | EP | claimed |
| US-11253686-B2 | Swallowable drug delivery device and methods of drug delivery | RANI THERAPEUTICS, LLC (US) | 2022-02-22 | — | — | US | claimed |
| US-11254660-B2 | Combinations for treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2022-02-22 | — | — | US | claimed |
| EP-3952855-A1 | COMBINATION THERAPY COMPRISING COMPOUNDS OF FORMULA (I) AND GLP-1 RECEPTOR AGONISTS | Genfit (FR) | 2022-02-16 | — | — | EP | claimed |
| EP-3952847-A1 | IMPLANTABLE POLYMER DEPOTS FOR THE CONTROLLED, SUSTAINED RELEASE OF THERAPEUTIC AGENTS | Foundry Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | claimed |
| CN-114040779-A | Conjugates of cell binding molecules containing branched linkers and cytotoxic agents | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| WO-2022028572-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-02-10 | — | — | WO | claimed |